Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Autor: Lesokhin, Alexander M., Tomasson, Michael H., Arnulf, Bertrand, Bahlis, Nizar J., Miles Prince, H., Niesvizky, Ruben, Rodrίguez-Otero, Paula, Martinez-Lopez, Joaquin, Koehne, Guenther, Touzeau, Cyrille, Jethava, Yogesh, Quach, Hang, Depaus, Julien, Yokoyama, Hisayuki, Gabayan, Afshin Eli, Stevens, Don A., Nooka, Ajay K., Manier, Salomon, Raje, Noopur, Iida, Shinsuke, Raab, Marc-Steffen, Searle, Emma, Leip, Eric, Sullivan, Sharon T., Conte, Umberto, Elmeliegy, Mohamed, Czibere, Akos, Viqueira, Andrea, Mohty, Mohamad

Publikováno v: Nature Medicine; 20230101, Issue: Preprints p1-9, 9p

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX

Autor: Kaufman, J. L., Dimopoulos, M., White, D., Benboubker, L., Cook, G., Leiba, M., Morton, J., Joy Ho, P., Kim, K., Takezako, N., Moreau, P., Sutherland, H. J., Magen, H., Iida, S., Kim, J. S., Miles Prince, H., Cochrane, T., Oriol, Albert, Bahlis, N. J., Chari, A., O'Rourke, L., Trivedi, S., Casneuf, T., Krevvata, M., Ukropec, J., Kobos, R., Avet-Loiseau, H., Usmani, S. Z., San-Miguel, J., Universitat Autònoma de Barcelona

Publikováno v: Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Blood Cancer Journal, Vol 10, Iss 11, Pp 1-10 (2020)
Blood Cancer Journal
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf52c1b21c245ed4d385bb3826621820
https://ddd.uab.cat/record/236598

Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

Autor: Foss, Francine, Horwitz, Steven, Pro, Barbara, Miles Prince, H., Sokol, Lubomir, Balser, Barbara, Wolfson, Julie, Coiffier, Bertrand

Publikováno v: Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-2 (2017)

Background Achievement of durable responses in patients with relapsed/refractory peripheral T cell lymphoma (PTCL) is challenging with current therapies, and there are few data regarding the potential benefits of continuing treatment in patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::facf336affda3b1a050048a1bd3f34ff
https://doi.org/10.1186/s13045-017-0518-8

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.